Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery

Guo, Jianwei; Gao, Xiaoling; Su, Linlin; Xia, Huimin; Gu, Guangzhi; Pang, Zhiqing; Jiang, Xinguo; Yao, Lei; Chen, Jun; Chen, Hongzhuan

doi:10.1016/j.biomaterials.2011.07.004

Cited by 528 publications

(365 citation statements)

References 50 publications

Supporting

Mentioning

353

Contrasting

Order By: Relevance

“…The emulsion/solvent evaporation approach was used to create SAL-NPs, as previously described (15). PLGA-PEG-COOH (30 mg) and salinomycin (5 mg) were dissolved in dichloromethane (2 ml) to form the drug solution, which was added into an aqueous sodium cholate solution (1%; 4 ml).…”

Section: Development Of Salinomycin-loaded Plga Nanoparticlesmentioning

confidence: 99%

“…Several salinomycin-loaded nanoparticles have been developed for its delivery to CSCs, and these have achieved an improved therapeutic effect over free salinomycin (13,14). Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are widely used due to their safety record in humans (15,16). PLGA nanoparticles are frequently modified with poly(ethylene glycol) (PEG) to increase their in vivo circulation.…”

Section: Introductionmentioning

confidence: 99%

“…PLGA nanoparticles are frequently modified with poly(ethylene glycol) (PEG) to increase their in vivo circulation. The PEGylation of nanoparticles significantly increases their passive targeting of tumors (15).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133 + ovarian CSCs. The results revealed that CD133-SAL-NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133-SAL-NPs efficiently bound to CD133 + ovarian cancer cells, resulting in an increased cytotoxic effect in CD133 + ovarian cancer cells, compared with the untargeted SAL-NPs and salinomycin. CD133-SAL-NPs reduced the percentage of CD133 + ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL-NPs, suggesting that CD133-SAL-NP targeted CD133 + ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133-SAL-NPs exerted improved therapeutic effects compared with SAL-NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133 + ovarian CSCs. CD133-SAL-NPs may therefore represent a promising approach for the treatment of ovarian cancer.

show abstract

Section: Development Of Salinomycin-loaded Plga Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Different cells including MDCK cells [17,20,24,29] , BCECs [19,26,33,40] , bEnd.3 cells [28,39] , and glioma cells [20,34,37,41] were used as in vitro cell models treated at doses ranging from 10 to 15,000 μ g/ml. Small size, positively charged and less hydrophilic NPs were associated with enhanced cellular uptake [17] .…”

Section: Uptake Efficiencymentioning

confidence: 99%

“…Among 29 papers cited in this review, 9 papers performed in vitro studies [20,23,24,31,33,37,38,40] , 8 papers focused on in vivo studies [13,15,16,18,21,25,27,30] , and 12 papers did both in vitro and in vivo studies [14,17,19,22,26,28,29,32,34,35,39,41] .…”

Section: Introductionmentioning

confidence: 99%

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Sabliov

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

Abstract:The blood-brain barrier (BBB), which protects the central nervous system (CNS) from unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many therapeutic agents such as hydrophilic and macromolecular drugs cannot overcome the BBB. One promising solution is the employment of polymeric nanoparticles (NPs) such as poly (lactic-co-glycolic acid) (PLGA) NPs as drug carrier. Over the past few years, significant breakthroughs have been made in developing suitable PLGA and poly (lactic acid) (PLA) NPs for drug delivery across the BBB. Recent advances on PLGA/PLA NPs enhanced neural delivery of drugs are reviewed in this paper. Both in vitro and in vivo studies are included. In these papers, enhanced cellular uptake and therapeutic efficacy of drugs delivered with modified PLGA/PLA NPs compared with free drugs or drugs delivered by unmodified PLGA/ PLA NPs were shown; no significant in vitro cytotoxicity was observed for PLGA/PLA NPs. Surface modification of PLGA/PLA NPs by coating with surfactants/polymers or covalently conjugating the NPs with targeting ligands has been confirmed to enhance drug delivery across the BBB. Most unmodified PLGA NPs showed low brain uptake ( < 1 % ), which indirectly confirms the safety of PLGA/PLA NPs used for other purposes than treating CNS diseases.

show abstract